TITLE

A semi-qualitative study of attitudes to vaccinating adolescents against human papillomavirus without parental consent

AUTHOR(S)
Brabin, Loretta; Roberts, Stephen A.; Kitchener, Henry C.
PUB. DATE
January 2007
SOURCE
BMC Public Health;2007, Vol. 7, p20
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: The first vaccine to prevent human papillomavirus (HPV) and cervical cancer has been licensed, and in future, vaccination may be routinely offered to 10-14 year old girls. HPV is a sexually transmitted virus and some parents may refuse consent for vaccination. Under-16s in the UK have a right to confidential sexual health care without parental consent. We investigated parents' views on making available HPV vaccination to adolescent minors at sexual health clinics without parental consent. Methods: This was a semi-qualitative analysis of views of parents of 11-12 year old school children collected as part of a population-based survey of parental attitudes to HPV vaccination in Manchester. Parents were firstly asked if they agreed that a well-informed child should be able to request vaccination at a sexual health clinic without parental consent, and secondly, to provide a reason for this answer. Ethical perspectives on adolescent autonomy provided the framework for descriptive analysis. Results: 307 parents answered the question, and of these, 244 (80%) explained their views. Parents with views consistent with support for adolescent autonomy (n = 99) wanted to encourage responsible behaviour, protect children from ill-informed or bigoted parents, and respected confidentiality and individual rights. In contrast, 97 parents insisted on being involved in decision-making. They emphasised adult responsibility for a child's health and guidance, erosion of parental rights, and respect for cultural and moral values. Other parents (n = 48) wanted clearer legal definitions governing parental rights and responsibilities or hoped for joint decision-making. Parents resistant to adolescent autonomy would be less likely to consent to future HPV vaccination, (67%) than parents supporting this principle (89%; p < 0.001). Conclusion: In the UK, the principle of adolescent autonomy is recognised and logically should include the right to HPV vaccination, but this may concern parents who would otherwise approve vaccination.
ACCESSION #
29361921

 

Related Articles

  • Comparing the HPV vaccines. Blamble, Deborah // Infectious Disease News;Apr2010, Vol. 23 Issue 4, p53 

    The article presents a discussion about the different types of human papillomavirus (HPV) vaccines, which include quadrivalent and bivalent.

  • ACIP reviews HPV vaccination in boys and men.  // Infectious Diseases in Children;Mar2010, Vol. 23 Issue 3, p36 

    This article discusses a study on the effectiveness of human papillomavirus vaccines for boys and men.

  • HPV vaccination not cost-effective in Netherlands. Adams, Stacey L.; Harris, Jason; Haigh, Christen // Hem/Onc Today;8/25/2009, Vol. 10 Issue 16, p23 

    The article focuses on a study which examined the cost-effectiveness of human papillomavirus (HPV) vaccination in the Netherlands.

  • HPV vaccines decreased the risk for variety of HPV-related diseases.  // Infectious Diseases in Children;Mar2010, Vol. 23 Issue 3, p32 

    This article discusses a study on the use of human papillomavirus (HPV) vaccines against different types 6, 11, 16 and 18.

  • Vaccinating men against HPV? Edwards, Blance; Jull, Andrew // Nursing Review (1175-2904);May2011, Vol. 12 Issue 1, p5 

    The article assesses the potential of vaccinations in avoiding contraction of the Human Papilloma Virus (HPV). The study was performed through a random controlled test, where 4,065 men aged from 16 to 23 were qualified and given 3 doses of 0.5-milliliter qHPV L1 vaccine on their arms. Results...

  • Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant (Cervarix). Elliott, William T.; Chan, James // Internal Medicine Alert;12/29/2009, Vol. 31 Issue 24, p190 

    The article evaluates Cervarix, a human papillomavirus (HPV) bivalent and recombinant vaccine for Types 16 and 18 from GlaxoSmithKline.

  • HPV vax uptake remains low in US, despite being "safe and effective".  // PharmacoEconomics & Outcomes News;Aug2014, Vol. 708 Issue 1, p6 

    The article discusses a research on human papillomavirus (HPV) vaccination in the U.S., in reference to the study "HPV vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014 - United States," by S. Stokley, et al., which appeared in the July 25,...

  • HPV vax catch-up programme could pay off in Norway.  // PharmacoEconomics & Outcomes News;Aug2014, Vol. 708 Issue 1, p6 

    The article discusses research on the human papillomavirus (HPV) vaccination in Norway, in reference to the studies "Too Late to vaccine? The incremental benefits and cost-effectiveness (CE) of a delayed catch-up (CP) program using the 4-valent HPV vaccine in Norway," by E.A. Burger, et al., and...

  • Successful school-based HPV vaccine program for boys.  // PharmacoEconomics & Outcomes News;Mar2015, Vol. 723 Issue 1, p27 

    The article discusses research being done on the school-based human papillomavirus (HPV) vaccine program for boys and girls in Prince Edward Island, Canada, which references a study by C. A. McClure et al. published in the February 27, 2015 issue of "Vaccine."

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics